Publication date: 6 April 2017
Source:Cell Stem Cell, Volume 20, Issue 4
Author(s): Naresh Mutukula, Yechiel Elkabetz
Recently in Science Translational Medicine, Bagó et al. (2017) reported an advance in treating glioblastoma using tumor-homing cytotoxic induced neural stem cells (h-iNSCTE). This approach circumvents problems associated with immune rejection and minimizes the bench-to-clinic time window critical for these patients.
Teaser
Recently in Science Translational Medicine, Bagó et al. reported an advance in treating glioblastoma using tumor-homing cytotoxic induced neural stem cells (h-iNSCTE). This approach circumvents problems associated with immune rejection and minimizes the bench-to-clinic time window critical for these patients.http://ift.tt/2p8CF0d
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου